Benzodiazepines act on the GABA-A receptor, the brain's primary inhibitory transmitter system. The mechanism is positive allosteric modulation — BZDs bind a specific site on the GABA-A receptor and enhance the frequency of chloride channel opening when GABA itself is bound. The result is amplified GABAergic inhibition: anxiety dampens, muscles relax, seizure activity quiets, sleep comes, memories don't form. One molecule, many effects, dose-dependent across the spectrum.
- Class
- Benzodiazepines
- Mechanism
- Positive allosteric modulators of GABA-A receptors — enhance frequency of chloride channel opening when GABA binds. Bind benzodiazepine site of α1βγ2 subunit.
- Typical dose
- Drug-specific
- Half-life
- Drug-specific (alprazolam short, diazepam very long via active metabolites)
- FDA indications
- Anxiety disorders, panic disorder, insomnia, alcohol withdrawal, seizures (status epilepticus), procedural sedation, catatonia, muscle spasm
- Key adverse effects
- Sedation, cognitive impairment (especially elderly), motor coordination impairment, falls, paradoxical disinhibition, anterograde amnesia, respiratory depression (especially with opioids), tolerance, dependence, withdrawal (can be life-threatening)
- Representative agents
- Alprazolam, lorazepam, clonazepam, diazepam, midazolam, oxazepam, temazepam, chlordiazepoxide
Black box: Concomitant use with opioids increases risk of profound sedation, respiratory depression, coma, death
Most useful when: short-term, defined purpose, no opioid combination, careful patient selection. Avoid in: history of substance use disorder, elderly (falls, cognitive impairment), pregnancy (first trimester), sleep apnea. Withdrawal seizure risk requires gradual taper after sustained use.
Therapeutic uses span: acute anxiety, panic, alcohol withdrawal, seizure rescue, procedural anxiolysis, catatonia, severe agitation. For the acute, defined-purpose problem, benzodiazepines work fast and reliably. For chronic use, the costs accumulate: tolerance develops, withdrawal becomes a problem, cognitive impairment compounds, fall risk rises in older patients, and combined opioid use carries a black-box warning for respiratory depression.
Benzodiazepines all act at one site — the GABA-A receptor — and all of their effects, therapeutic and problematic, flow from potentiating that single channel.
Mechanism note: Benzodiazepines are fast and effective for acute indications but the same GABA-A mechanism drives tolerance, dependence, cognitive cost, and fall/overdose risk — making chronic use a longevity liability.
The class differs by half-life and route. Short-acting agents (alprazolam, oxazepam, midazolam) produce more rebound effect between doses and more severe withdrawal but less accumulation. Long-acting agents (diazepam, clonazepam, chlordiazepoxide) produce smoother coverage but accumulate, particularly in elderly patients. The half-life shapes the clinical character more than any other property.
Three subgroups deserve specific mention: LOT — lorazepam, oxazepam, temazepam — are glucuronidated only (no CYP oxidation), so they don't accumulate in hepatic impairment or elderly patients to the degree other BZDs do. They're often the right choice in those populations.
The opioid-BZD synergy is the central safety story of the past decade. Both classes suppress brainstem respiratory drive; combined, the respiratory depression is non-additive — substantially more dangerous than either alone. The black-box warning on both classes was added in 2016, and overdose data have supported it. Coprescription should be exceptional, time-limited, and with naloxone available.
For appropriate uses, benzodiazepines remain irreplaceable. For everything else, the trade-offs require explicit thought.